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Malignant anterior skull base neoplasms are rare and heterogeneous tumors that can spread to var-ious adjacent sites such as the orbit, cavernous 
sinus, and brain. Nowadays, treatment modalities include 
surgery, radiotherapy, chemotherapy, or a combination of 
these. Craniofacial resection,13 introduced in the 1960s, 
dramatically improved local control of the disease and is 
still considered the gold standard treatment for anterior 
skull base malignancies. Nonetheless, the procedure has 
been associated with nonnegligible postoperative compli-
cation (36.3%) and perioperative mortality (4.7%) rates.7 
Significant advances in endoscopic and minimally inva-
sive surgical approaches have revolutionized the treatment 
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Object. For several decades, the exclusive purpose in the management of anterior skull base malignancies has 
been to increase survival rates. Recently, given the improved prognosis achieved, more attention has been focused 
on quality of life (QOL) as well. Producing data on QOL in anterior skull base cancers is hampered by the rarity of 
the neoplasm and the lack of specific questionnaires. The purpose of this study was to assess health-related QOL in 
a large and homogeneous cohort of patients affected by anterior skull base cancers who had undergone endoscopic 
endonasal resection.
Methods. The authors conducted a retrospective review of patients treated for sinonasal and skull base cancers 
via an endoscopic endonasal approach at two Italian tertiary care referral centers. All patients were asked to complete 
the Anterior Skull Base Surgery Questionnaire to evaluate their QOL before and 1 month and 1 year after surgical 
treatment. To assess which parameters affect QOL, the study population was divided into subgroups according to age, 
sex, stage of disease, surgical approach, and adjuvant therapy.
Results. One hundred fifty-three patients were enrolled in this study according to the adopted inclusion criteria. 
Overall QOL started at a score of 4.68 for the preoperative period, sharply decreased as far as a score of 4.03 during 
the 1st postoperative month, and rose again to a score of 4.59 over the course of 1 year after treatment, with a signifi-
cant difference among the 3 values (p < 0.05). The specific symptoms and physical status domains registered poorer 
results at the 1-year assessment (4.00 and 4.71, respectively) than at the preoperative assessment (both domains 4.86), 
with a statistically significant reduction in scores (p < 0.05). Worse outcomes were associated with several variables: 
age > 60 years (difference of 0.21 points between the preoperative and 1-year period, p < 0.05), expanded surgical ap-
proaches with transnasal craniectomy (decrease of 0.20 points between the preoperative and 1-year period, p < 0.05), 
and postoperative radiotherapy (score of 4.53 at the 1-year period vs 4.70 in patients without any adjuvant treatment, 
p < 0.05). No statistically significant differences were found when analyzing the study population according to sex (p 
> 0.1) and T classification of disease at presentation (p > 0.05).
Conclusions. Radical endoscopic endonasal resection led to either complete or at least partial recovery of patient 
QOL within the 1st postoperative year.
(http://thejns.org/doi/abs/10.3171/2013.8.JNS13296)
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Abbreviations used in this paper: ASBS-Q = Anterior Skull 
Base Surgery Questionnaire; CHT = chemotherapy or radiochemo-
therapy; ER = endoscopic resection; ERTC = ER with transnasal 
craniectomy; QOL = quality of life; RT = radiotherapy; T0 = no 
postoperative therapy.
This article contains some figures that are displayed in color 
on line but in black-and-white in the print edition. 
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of anterior skull base cancers. Selected lesions can be re-
moved without facial incision or external craniotomy by 
using a purely endonasal endoscopic approach. Data from 
several centers worldwide have clearly demonstrated that 
endoscopic endonasal surgery, when properly planned and 
in expert hands, can be considered a sound alternative to 
traditional open approaches, with comparable oncological 
control rates but shorter hospital stays, reduced morbidity, 
and fewer complications.10,16 From a clinical viewpoint, in 
the case of similar efficacy among the available options, the 
type of treatment should be chosen according to the low-
est possible impact on the patient’s quality of life (QOL). 
Unfortunately, there is a paucity of published data concern-
ing QOL in skull base surgery, with few papers focusing 
especially on external surgical approaches. Moreover, the 
few reports analyzing QOL in endoscopic endonasal ap-
proaches present several flaws: a small number of patients 
studied, heterogeneity of disease in terms of histology and 
localization, and heterogeneity of treatment. Our purpose 
in the present study was to assess health-related QOL in a 
homogeneous cohort of patients affected by anterior skull 




We retrospectively reviewed patients who had un-
dergone endoscopic endonasal resection of sinonasal and 
anterior skull base malignancies between June 1997 and 
December 2010 at the Departments of Otorhinolaryn-
gology of the Universities of Insubria and Brescia. Epi-
demiological and clinical data, surgical reports, data on 
adjuvant therapy and complications, and follow-up in-
formation were retrieved from a database dedicated to 
neoplasms of the sinonasal tract. Two teams sharing the 
same philosophy concerning clinical and surgical strate-
gies had performed the surgical procedures. The surgical 
technique, complications, and outcomes have been de-
scribed in detail elsewhere.16,21 Patients in this study were 
selected according to the following criteria: affected by 
malignant neoplasm of the anterior skull base and sino-
nasal tract; treated via an endoscopic endonasal resection 
with curative intent; alive with or without evidence of dis-
ease at the end of the 1st postoperative year; able to read 
and write, without severe psychopathological or cognitive 
impairment, and able to give informed consent to partici-
pate in this survey; and an age between 18 and 90 years 
at the moment of the interview. The local ethics board 
approved this study.
Anterior Skull Base Surgery Questionnaire
Quality of life outcomes were assessed using the An-
terior Skull Base Surgery Questionnaire (ASBS-Q), whose 
development, reliability, and validity have already been de-
scribed.9 Answers to the 35 questions in the ASBS-Q were 
expressed on an ordinal scale, with scores ranging from 1 
(worst QOL) to 5 (best QOL). Items in the ASBS-Q were 
divided into 6 relevant domains—role of performance, im-
pact on emotions, pain, physical function, specific symp-
toms, and vitality—to determine which of them mainly af-
fected QOL during the different periods tested. The Cron-
bach a values for each domain were greater than 0.8.9 The 
questionnaire was administered to patients either in person 
or through a telephone interview. An independent physi-
cian performed all interviews to avoid any bias that might 
stem from surgeon-patient interaction.
Assessment Periods and Overall QOL
Patients were asked to answer the questionnaire re-
ferring to 3 different periods: preoperatively, 1 month 
after surgery, and 1 year after surgery. The preoperative 
period was assessed to obtain a reference value for QOL, 
the 1-month period was helpful to investigate how much 
the resection and its extension had affected the patient’s 
QOL, and the 1-year period was assessed to evaluate the 
long-term evolution of QOL, including the effects of dif-
ferent protocols of adjuvant therapy. All the patients en-
rolled in this study filled in the questionnaires referring to 
all 3 time points. We evaluated the median score for each 
period analyzed.
Variables Affecting QOL
The study population was further divided into sub-
groups according to demographic and clinical features to 
predict which of these factors might have affected QOL. 
It was stratified into 2 subgroups for each of the following 
categories: sex (male and female), age at surgery (≤ 60 
and > 60 years), and extent of resection (sinonasal com-
partment only, or endoscopic resection [ER]; or extension 
toward the anterior cranial fossa, or endoscopic resection 
with transnasal craniectomy [ERTC]), with the resulting 
need for skull base reconstruction.21 The study popula-
tion was also stratified into 5 subgroups according to the 
T classification of disease at diagnosis (T1–T4b). For this 
purpose, all tumors were staged according to the 2010 
American Joint Committee on Cancer Staging Manual 
(7th edition), arbitrarily including all histotypes. The 
population was also divided into 3 subgroups according 
to the postoperative therapeutic protocol. The T0 sub-
group included the patients who had not undergone any 
postoperative therapy, the RT subgroup was composed of 
patients subjected to postoperative radiotherapy, and the 
CHT subgroup included patients who submitted to post-
operative chemotherapy or radiochemotherapy.
Statistical Analysis
A commercially available computer software pack-
age (IBM SPSS for Windows, version 19.0) was applied. 
To compare median values of the different periods ana-
lyzed, we used the Friedman test, obtaining a nonpara-
metric 1-way repeated measurement ANOVA by ranks. 
To compare median values of the different subgroups, we 
used the Kruskal-Wallis test, which is a nonparametric 
test for independent samples. A p value ≤ 0.05 was con-
sidered statistically significant.
Results
Of the 320 patients surgically treated for skull base 
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malignancies at our centers, 167 were excluded from 
our study for several reasons: combined transcranial ap-
proach performed, patient death, patient untraceable, and 
so forth (Fig. 1). Therefore, 153 patients were included in 
the study, and their clinical and pathological features are 
summarized in Table 1.
Overall QOL
The median values of overall QOL referring to the 
analyzed checkpoints started at 4.68 for the preoperative 
period, decreased as far as 4.03 for the 1-month post-
treatment period, and rose again to a score of 4.59 for the 
1-year postoperative period, with a significant difference 
among the 3 values (p < 0.05; Fig. 2A).
Domains of QOL
Globally, we reported lower scores at the 1-month 
period for every domain than at the other 2 periods, with 
statistically significant differences (p < 0.05; Fig. 2B and 
Table 2). In analyzing the QOL domains individually, we 
noted that the emotion and performance fields had better 
scores in the 1-year period (4.80 for both) than in the pre-
operative period (4.60 and 4.67, respectively), indicating 
a significant increment (p < 0.05). No statistically signifi-
cant differences were recorded between the preoperative 
and 1-year vitality and pain domains. The specific symp-
toms and physical status domains had poorer results in 
the 1-year period (4.00 and 4.71, respectively) than in the 
preoperative assessment (both 4.86), showing a statisti-
cally significant reduction (p < 0.05). When analyzing in 
detail the specific symptoms domain, the areas with the 
worst results 1 year after surgery were those concerning 
the sense of smell, nasal secretions, and the sense of taste, 
with scores of 1.78, 3.64, and 3.69, respectively, scores 
inferior to those reported in the preoperative period, with 
statistically significant differences (2.76, 1.09, and 1.07 
points, respectively; p < 0.05). The tears and eyesight do-
mains registered lower scores at the 1-year period than at 
the preoperative period, but without statistically signifi-
cant differences. Appetite and appearance domains had 
Fig. 1. Selection criteria for the population enrolled in the study. CER 
= cranioendoscopic resection; DOD = died of disease.
TABLE 1: Clinical and demographic features of 153 patients who 




  adenocarcinoma 65
  carcinoma group (squamous cell, adenoid- 
  cystic, undifferentiated)
34
  olfactory neuroblastoma 24
  mucosal melanoma 6
  other histotypes 24
age at surgery in yrs† 
  ≤60 70 (45.7)
  >60 83 (54.2)
sex
  M 105 (68.6)
  F 48 (31.4)
classification of disease
  T1 43 (28.1)
  T2 42 (27.4)
  T3 26 (17.0)
  T4a 19 (12.4)
  T4b 23 (15.0)
surgical approach
  ER 49 (32.0)
  ERTC 104 (68)
postop complication 
  CSF leak 4
  pneumocephalus 2
  brain abscess 1
  meningitis 1
adjuvant therapy
  none 66 (43.14)
  RT 77 (50.33)
  CHT 6 (3.92)
  RT + CHT 4 (2.61)
follow-up status‡ 
  NED 151 (98.7)
  AWD 2 (1.3)
* AWD = alive with disease; NED = no evidence of disease.
† Mean age was 58.8 years.
‡ Mean follow-up was 53.1 months.
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similar scores for the 1-year and preoperative periods, in-
dicating that the treatments had no impact on these fields.
Variables Affecting QOL 
Patient Sex. In the male subgroup we recorded a com-
plete recovery of overall QOL, without any statistically 
significant difference between the preoperative (4.68) and 
1-year (4.63) periods (p > 0.05). Detailed analysis of the 
QOL domains revealed that no significant differences 
were recorded in performance, vitality, physical function, 
and pain. On the other hand, the emotions domain had a 
1-year score of 4.80, higher than the preoperative score of 
4.60; this difference reached statistical significance (p < 
0.05). The specific symptoms domain had a 1-year score 
of 4.00, lower than the preoperative score of 4.86, indicat-
ing a statistically significant difference (p < 0.05). In the 
female subgroup we recorded a statistically significant 
difference between the preoperative and 1-year scores (p 
< 0.05), but no significant differences were recorded in 
the performance, physical function, emotions, and pain 
domains. On the other hand, the vitality and specific 
symptoms domains had lower scores at the 1-year period 
than at the preoperative period, showing a statistically 
significant difference (p < 0.05). However, when com-
paring the scores of overall QOL in the male and female 
subgroups, we found no statistically significant difference 
in the 3 periods analyzed (p > 0.05; Fig. 3B). Moreover, 
scores in the female group were lower than those in the 
Fig. 2. A: Median values of overall QOL for all enrolled patients for each period tested. The 3 values were statistically different 
(p < 0.05). B: Radar chart depicting the median values of the QOL domains in the different periods tested. Pre-op = preopera-
tive period; 1M = 1-month postoperative period; 1Y = 1-year postoperative period.
TABLE 2: Median values of the QOL domains and differences between the different periods tested*
QOL Domain
Score Points 
Preop 1M 1Y 1M − Preop 1Y − 1M 1Y − Preop
performance 4.67 4.00 4.80 −0.67† 0.80† 0.13†
physical function 4.86 4.14 4.71 −0.71† 0.57† −0.14†
vitality 4.71 4.14 4.71 −0.57† 0.57† 0.00
pain 5.00 4.00 5.00 −1.00† 1.00† 0.00†
specific symptoms 4.86 3.71 4.00 −1.14† 0.29† −0.86†
  appetite 4.78 4.13 4.59 −0.65† 0.46† −0.19†
  taste 4.75 3.35 3.69 −1.41† 0.34† −1.07†
  smell 4.54 1.67 1.78 −2.87† 0.11† −2.76†
  appearance 4.91 4.71 4.73 −0.20† 0.03 −0.18†
  nasal secretions 4.73 4.20 3.64 −0.53† −0.56† −1.09†
  tears 4.79 4.12 4.32 −0.67† 0.20† −0.47†
  eyesight 4.86 4.51 4.41 −0.35† −0.10 −0.46†
influence on emotions 4.60 4.20 4.80 −0.40† 0.60† 0.20†
* 1M = 1 month after surgery; 1Y = 1 year after surgery. 
† Statistically significant at p < 0.05, Friedman test.
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male group in all QOL domains, but we found no statisti-
cally significant difference between the 2 groups in any of 
the periods analyzed (p > 0.1).
Patient Age. In the younger population (age ≤ 60 
years), we recorded no statistically significant differ-
ence in overall QOL between the preoperative and 1-year 
scores. In contrast, in the over-60 group we found a sta-
tistically significant difference of 0.21 points (p < 0.05) 
between the preoperative and 1-year periods (Figs. 3A 
and 4A–B). Remarkably, at the 1-month period, the older 
group had lower scores in the physical status and specific 
symptoms domains than the younger group, with a sig-
nificant difference of 0.43 and 0.14 points, respectively (p 
< 0.05; Fig. 4C).
Resection. In the ER group, we did not find any sta-
tistically significant differences in overall QOL (p > 0.05) 
between preoperative and 1-year values, revealing com-
plete recovery of the parameter measured. Conversely, 
in the ERTC group a statistically significant decrease of 
0.20 points (p < 0.05) was seen between the preoperative 
and 1-year scores (Fig. 3C). Interestingly, we recorded a 
statistically significant difference between the 2 surgical 
subgroups at the 1-month period (p < 0.05), confirming 
that the extent of surgery had an impact on overall QOL 
especially in the early postoperative period. However, the 
impact of surgical approach on the overall QOL seemed 
to decrease throughout the postoperative time, to the 
point that no statistically significant difference between 
the 2 subgroups was found 1 year after surgery (p > 0.05). 
More specifically, we observed better 1-month scores 
in the vitality, pain, and specific symptoms domains in 
the ER group than in the ERTC group, with statistically 
significant differences of 0.21, 0.20, and 0.33 points, re-
spectively (p < 0.05; Fig. 4D–F). On the other hand, these 
differences were less at the 1-year period, with statisti-
cally significant better scores for ER only in the specific 
symptoms domain (p < 0.05).
Stage of Disease. Regarding the T classification of 
disease, we found no statistically significant difference in 
overall QOL between the preoperative and 1-year scores 
(p > 0.05). In contrast to what we observed in the T1–T4a 
subgroups, we did not record any differences in overall 
QOL between the 1-month and 1-year periods (p > 0.05) 
in patients with T4b cancers, highlighting the limited re-
covery gained by this subset of patients during the post-
operative period (Fig. 3E). However, when comparing the 
Fig. 3. The trend of overall QOL during the different periods tested, analyzed by stratifying the population according to age (A), 
sex (B), surgical approach (C), adjuvant therapy (D), and T classification of disease (E). PRE = preoperative period.
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5 subgroups, we found no statistically significant differ-
ence in overall QOL for the periods tested (p > 0.05).
Adjuvant Therapy. We did not find any significant 
difference in overall QOL (p > 0.05) between the preop-
erative and 1-year period in the T0 subgroup, pointing out 
complete recovery of the parameter measured. In the RT 
subgroup, the 1-year value of overall QOL was statisti-
cally significantly lower than the preoperative value (p < 
0.05; Fig. 3D). These results highlight how the RT patients 
required more time to recover their preoperative lifestyle 
than those given no postoperative treatment. On the other 
hand, in the CHT subgroup there was no significant dif-
ference among the 3 periods analyzed (p > 0.05) in terms 
of overall QOL. However, the lack of statistical power in 
this subgroup was probably due to the small sample size 
(Fig. 4G–H). When comparing the 3 subgroups, we found 
no statistically significant difference (p > 0.05) among the 
values at the 1-month period (4.10, 4.00, and 3.81 for the 
T0, RT, and CHT groups, respectively). These data are 
explained by the fact that the adjuvant therapies had not 
yet begun in this early postoperative period. In contrast, 
when comparing the 3 subgroups at the 1-year period, 
the T0 subgroup showed higher overall QOL scores than 
the RT subgroup, which in turn recorded higher scores 
than the CHT subgroup (T0 = 4.70 > RT = 4.53 > CHT = 
3.74), with statistically significant differences (p < 0.05). 
Similarly, when analyzing in detail the specific symptoms 
domain at the 1-year period, we found the scores progres-
sively decreasing from the T0 (4.14) to the RT (4.00) and 
CHT (3.00) subgroups, with statistically significant dif-
ferences (p < 0.05; Fig. 4I).
Discussion
The goals of treatment for sinonasal and skull base 
cancers are now balanced between maximizing oncologi-
cal control and minimizing the functional disability of 
patients. Advantages and limits of endoscopic endonasal 
techniques with respect to traditional approaches are well 
known.6,10,16 In the last few years, encouraging oncological 
results have emerged from large case series with long-term 
follow-ups, confirming the safety and efficacy of endo-
scopic endonasal resection in the management of sinonasal 
and anterior skull base malignancies. Furthermore, recent 
meta-analyses and review articles have sufficiently shown 
that endoscopic transnasal resection, in selected cases and 
in expert hands, can lead to disease-control and survival 
rates comparable with those for traditional open approach-
es.11,17 Nowadays, however, when evaluating long-term out-
comes, endoscopic approaches should be compared with 
Fig. 4. Radar charts of QOL domains during the different periods tested, stratifying the population according to age (A–C), 
surgical approach (D–F), and adjuvant therapy (G–I). Comparisons between these subgroups are reported only for the most 
significant periods (C, F, and I).
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traditional external approaches in terms of not only safety 
and efficacy but also QOL. And, while sound data regard-
ing the safety and efficacy of endoscopic techniques are 
now available, the same is not true for the topic of QOL. In 
this respect, the systematic evaluation of QOL and its clini-
cal variables is a modern method of comparing different 
surgical approaches with similar efficacies. At the moment, 
only limited and confusing data are available regarding 
QOL in endoscopic endonasal skull base surgery. In this 
context, the overall heterogeneity of the case series are at-
tributable to different pathologies (benign, malignant, and 
pituitary tumors together), tumor sites (anterior, middle, 
and lateral skull base), surgical corridors, and reconstruc-
tive methods, which are confounding factors. In addition, 
the small sample of cases often does not allow adequate 
stratification of the population into subgroups. To further 
complicate matters, different authors have assessed QOL 
using various questionnaires, which have not always been 
validated. 
To overcome these limits, we analyzed the evolution 
of QOL in a large cohort of patients with anterior skull 
base malignancies treated according to a standardized 
technique.16 We used a questionnaire initially designed 
for open anterior skull base surgery9 but subsequently 
validated for endoscopic endonasal surgery as well.19 To 
reduce variability, the questionnaire was administered by 
the same investigators. In this way we tried to produce 
data as homogeneous as possible. Our results seemed to 
suggest that overall QOL decreases sharply during the 
1st postoperative month and tends to improve over the 
course of 1 year until it reaches at least partial recovery. 
This finding agrees with results in previous reports.4 In 
our analysis, the most critical period appeared to be the 
early postoperative one. In this period, the main domains 
affected were pain and specific symptoms: patients prin-
cipally complained of loss of taste and smell but also re-
ported nasal discharge and crusting. These last 2 symp-
toms produce a significantly negative impact on patient 
QOL during the normal postoperative process of healing. 
Pant et al. found similar results when dealing with benign 
and malignant anterior skull base tumors.19 In their study, 
QOL was assessed using the ASBS-Q and seemed to be 
affected mainly in the specific symptoms domain during 
the first 1–3 postoperative months. However, in agreement 
with our findings, the sinonasal morbidity gradually im-
proved with time, reaching partial or complete recovery 
from 6 months to 1 year after the endoscopic endonasal 
procedure. Furthermore, the increased sinonasal morbid-
ity following endoscopic skull base surgery seemed to be 
affected by the complexity of the surgical procedures and 
the use of nasoseptal flaps.5,19 Our data also confirmed 
that the more extensive the surgery, the greater the im-
pact on patient QOL. In fact, the worst score was found in 
patients who had undergone transnasal craniectomy with 
skull base reconstruction rather than in the subgroup of 
patients who did not require such an extended approach. 
Nevertheless, the differences between these 2 subgroups, 
which were particularly evident at the 1-month period, 
decreased during the 1st year after surgery. In addition, 
reports on traditional open approaches also confirmed 
that QOL is influenced by the extent of surgery.8 In this 
respect, the only study to compare subcranial and endo-
scopic approaches showed that patients treated endoscop-
ically had significantly better QOL scores in the physical 
function and emotions domains than those treated with 
open surgery.1 As stated, our study presents several strong 
points with regard to previous publications: a validated 
questionnaire, the same investigators to administer the 
questionnaire, and a large and homogeneous cohort of 
patients with similar pathologies and treatments. 
In this respect, a recent meta-analysis2 has shown a 
statistically significant difference in QOL between pa-
tients treated for benign and those treated for malignant 
tumors, no matter which type of approach has been uti-
lized. These data could be expected not only because of 
general cancer-related influences on the different aspects 
of QOL, but also for the impact of early and long-term 
morbidity due to the adjuvant therapies. In fact, our data 
showed a statistically significant deterioration in the QOL 
of patients treated with postoperative radiotherapy, espe-
cially in the specific symptoms domain. Moreover, pa-
tients in this subset had only a partial recovery of their 
former QOL at the 1-year period, requiring more time to 
return to their normal lifestyle than the patients who did 
not receive postoperative treatment. These results are in 
accordance with those of previous studies describing a 
significant deterioration in QOL and an increase in de-
pression after adjuvant radiation therapy for skull base 
cancer.8,12,18 When evaluating data in terms of the T clas-
sification of disease, we found no statistically significant 
difference among the 5 subgroups of our study population. 
This result seems to suggest that the stage of disease does 
not have a direct impact on overall QOL. However, when 
analyzing each subgroup separately by using the Fried-
man test, we observed a full recovery of overall QOL at 
the 1-year period in all cases, except in the T4b patients, 
who only partially regained their preoperative lifestyle. 
This result is not easily understood given the fact that, in 
most cases, these patients undergo procedures similar to 
those used in the T4a patients. A possible explanation in 
some cases could be related to the extent of resection; that 
is, T4b lesions might involve the pterygopalatine fossa or 
the nasopharynx, whose removal would certainly increase 
functional impairment. Another explanation for this find-
ing could be that preoperative counseling is less optimis-
tic for the T4b patients; therefore, the subsequent impact 
on their QOL would be greater. Honestly speaking, a clear 
and sound reason has not been found. The demographic 
features of our patient cohort were investigated to find 
a significant predictor of QOL. Recent case studies on 
endoscopic skull base surgery evaluating QOL (using the 
ASBS-Q) have described the female sex as a significant 
predictor of a poor outcome.3 Our data do not confirm 
this difference. Similarly, Palme et al. did not find sex to 
be a prognostic factor, although they used tools different 
from ours.18 When evaluating the role of age, we observed 
only partial recovery of QOL in the patients over 60 years 
of age at the 1-year period, whereas younger patients had 
a complete recovery of their preoperative lifestyle. A sim-
ilar conclusion, although based on a heterogeneous group 
of patients treated via open approaches, was reached by 
Gil et al.8 So, based on our results, the age factor should 
P. Castelnuovo et al.
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not be considered to be of minor importance in determin-
ing postoperative outcome. Altogether, the data from our 
study are encouraging, showing that endoscopic endona-
sal surgery in patients with skull base cancers leads to a 
complete recovery of overall QOL 1 year after surgery. 
Variables associated with a worse QOL were an age > 60 
years, expanded ERTC, and postoperative radiotherapy.
Obviously, our study has limitations. First of all, the 
retrospective nature of the study design could influence 
the interpretation of data, but it represents the only means 
to collect a significant cohort of patients given the very 
recent introduction of endoscopic transnasal approaches. 
Moreover, we did not consider the recurrence of disease 
as a factor affecting QOL. The burden of living with dis-
ease recurrence is obviously substantial, and the disap-
pointment of primary treatment failure can naturally in-
fluence several aspects of a patient’s well-being. However, 
in our oncological experience, QOL was impaired even 
when patients with no actual evidence of disease were 
concerned that the cancer might recur. In addition, the 
impact of complications on QOL was not analyzed; how-
ever, we have had so few complications (8 [5.2%] in 153 
patients, as detailed in Table 1) that their analysis would 
not have reached a statistically significant value and thus 
would not have significantly modified the global meaning 
of our study. Last but not least, there is presently no con-
sensus regarding the best instrument for assessing QOL. 
In our study, we did not adopt the 22-Item Sino-Nasal 
Outcome Test (SNOT-22) questionnaire15 because we be-
lieve that sinonasal morbidity can be equally estimated 
using only the specific symptoms domain of the ASBS-Q. 
Other authors agree with this viewpoint.2
Conclusions
The evolution of skull base surgery calls for a holis-
tic evaluation of outcomes, not limited to survival rates 
alone. In our opinion, rigorous measurement of function-
al outcomes and QOL is of paramount importance. We 
maintain that there is a strong need for prospective multi-
center studies to more accurately assess the QOL features 
of patients with anterior skull base cancers treated with 
endoscopic endonasal surgery in relation to other treat-
ments. In this respect, Patel suggests a need for meticu-
lous multiinstitutional data collection regarding function-
al outcomes in patients who have undergone skull base 
surgical procedures.20 For this purpose, a large Internet-
based database of cases with malignant sinonasal and 
skull base tumors treated via an endoscopic endonasal 
approach has been set up to collect the clinical history 
of patients, imaging data, pathological findings, surgical 
management, and postoperative treatments.14 Obviously, 
prospective QOL evaluation should also be included in 
the pre- and posttreatment assessment of these patients. 
Incorporating a QOL questionnaire into the standard of 
care of patients with skull base cancers will enable the 
surgeon to better understand, in a more holistic fashion, 
the impact of treatment on the daily lifestyle of these pa-
tients and consequently to identify the best treatment op-
tion for a given patient. This is particularly true in the 
case of new treatment proposals.
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